Search Press releases Keywords From To 7 Mar 2025 Share Repurchase Program 2025 to cover UCB's Long Term Incentive Plans for employees Read More 7 Mar 2025 BIMZELX[®] (bimekizumab-bkzx) five-year data at AAD 2025 showed sustained skin clearance and long-term efficacy in moderate-to-severe plaque psoriasis Read More 7 Mar 2025 BIMZELX[®] (bimekizumab-bkzx) two-year data at AAD showed potential to eliminate draining tunnels in hidradenitis suppurativa (HS), and reduction in disease burden Read More 27 Feb 2025 On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth Read More 12 Feb 2025 BIMZELX[®]▼(bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in hidradenitis suppurativa (HS) Read More 31 Jan 2025 RYSTIGGO[®]▼(rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods Read More Pagination First page Previous page Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Page 2 of 66 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
